A recurrent de novo mutation in KCNC1 causes progressive myoclonus epilepsy
Anna-Elina Lehesjoki and colleagues report exome sequencing of 84 cases of progressive myoclonus epilepsy (PME) and targeted resequencing of an additional 28 cases. They identify de novo mutations in KCNC1 in 13 cases and mutations in genes not previously associated with PME, including PRNP , SACS a...
Saved in:
Published in | Nature genetics Vol. 47; no. 1; pp. 39 - 46 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York
Nature Publishing Group US
01.01.2015
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Anna-Elina Lehesjoki and colleagues report exome sequencing of 84 cases of progressive myoclonus epilepsy (PME) and targeted resequencing of an additional 28 cases. They identify
de novo
mutations in
KCNC1
in 13 cases and mutations in genes not previously associated with PME, including
PRNP
,
SACS
and
TBC1D24
, in additional cases.
Progressive myoclonus epilepsies (PMEs) are a group of rare, inherited disorders manifesting with action myoclonus, tonic-clonic seizures and ataxia. We sequenced the exomes of 84 unrelated individuals with PME of unknown cause and molecularly solved 26 cases (31%). Remarkably, a recurrent
de novo
mutation, c.959G>A (p.Arg320His), in
KCNC1
was identified as a new major cause for PME. Eleven unrelated exome-sequenced (13%) and two affected individuals in a secondary cohort (7%) had this mutation.
KCNC1
encodes K
V
3.1, a subunit of the K
V
3 voltage-gated potassium ion channels, which are major determinants of high-frequency neuronal firing. Functional analysis of the Arg320His mutant channel showed a dominant-negative loss-of-function effect. Ten cases had pathogenic mutations in known PME-associated genes (
NEU1
,
NHLRC1
,
AFG3L2
,
EPM2A
,
CLN6
and
SERPINI1
). Identification of mutations in
PRNP
,
SACS
and
TBC1D24
expand their phenotypic spectra to PME. These findings provide insights into the molecular genetic basis of PME and show the role of
de novo
mutations in this disease entity. |
---|---|
Bibliography: | SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-2 content type line 23 Author Contributions Study design and management: S.F.B., L.M.D., A.P., A.-E.L. Coordination of the collection of study subjects and clinical data: S.F.B., K.L.O., M.A.B., A.-E.L. Subject ascertainment and phenotyping: S.F.B., K.L.O., L.C., S.F., R.M., E.A., F.A., A.G., P.T., L.L., I.E.S., C.C., A.F., E.F., J.A., A.A., B.B., E.S., M.T., P.R., M.D.K., C.O., D.M.A., B.A.E., A.C., M.L., E.L., V.S., J.M., M.P., A.E., B.K., M.D., R.S.M., R.S., Z.A., B.B.-Z. Analysis of the exome sequencing data: M.M., S.Mar. Sanger sequencing and sequence data analysis, mosaicism analysis: M.M., M.A.B., T.J., S.E.H., M.S.H. Interpretation of genetic data: M.M., S.F.B., L.M.D., A.P., A.-E.L. Evaluation of the mutation rate in KCNC1: K.E.S., M.J.D. Functional analysis and interpretation: S.Mal., S.P., H.L. Manuscript writing: M.M., S.F.B., L.M.D., K.L.O., S.Mal., H.L., A.P., A.-E.L. All authors critically revised the manuscript. |
ISSN: | 1061-4036 1546-1718 1546-1718 |
DOI: | 10.1038/ng.3144 |